Login to Your Account

Cornerstone's Lixivaptan Faces Mixed FDA Reviews at CRDAC

By Mari Serebrov
Washington Editor

Wednesday, September 12, 2012
Cornerstone Therapeutics Inc. will put its acquisition of Cardiokine Inc. to the test Thursday as it debuts Cardiokine's lone compound, lixivaptan, for the FDA's Cardiovascular and Renal Drugs Advisory Committee (CRDAC).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription